News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

February 27, 2023 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
February 22, 2023 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 22, 2023 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 21, 2023 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023 FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
February 13, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 5, 2023 Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
January 3, 2023 Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 16, 2022 Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy